Aclaris Therapeutics (ACRS) Reports Q2 Loss of $0.62/Share

Aclaris Therapeutics (NASDAQ: ACRS) reported Q2 EPS of ($0.62), versus ($1.52) reported last year.

For earnings history and earnings-related data on Aclaris Therapeutics (ACRS) click here.

You May Also Be Interested In

• Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
• Berenberg sees Vodafone upside from cash flow gains, German consolidation
• Citi cuts Gildan Activewear price target to Cdn$47